more aggressively. Cox-regression analysis did not find independent predictors of remission or relapse. Conclusions: The outcome of the patients with FHN we investigated was encouraging. Recurrences are limited to the first 4 years following diagnosis, allowing progressive withdrawal of immunosuppression in patients achieving remission. Evaluation of risk factors for adverse outcome is necessary especially in pre-pubertal children.
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I N T R O D U C T I O N
Full-house nephropathy (FHN) is a rare renal disease characterized by a variety of glomerular lesions typically accompanied by extensive deposition of all classes of immunoglobulins and complement components along different sites of the glomerulus, as revealed by immunofluorescence (IF) analysis [1] . It is commonly observed in systemic lupus erythematosus (SLE) and labelled as 'lupus nephritis' (LN), and it frequently associates with the highly suggestive tubuloreticular inclusions (TRIs) [2] . Many other conditions however, such as membranoproliferative glomerulonephritis (MPGN) and even cases of Henoch-Shönlein purpura nephropathy and other immune complex-mediated glomerulonephritis associated with hepatitis B and C or HIV viruses, can present a pattern of 'full-house' IF [3] .
Until recently, many cases of FHN without clinical or serological evidence of systemic disease have been defined as 'seronegative LN', reflecting the concept that FHN may represent the renal presentation of an 'incomplete lupus' rather than a distinct pathological entity [4] .
Indeed, in a minority of cases the possibility of a progression over time to overt SLE cannot be excluded [1] . Due to the broad similarity of renal lesions to LN, these patients usually are treated with immunosuppressive drugs in a variety of combinations based on the severity of histological features. Overall, data on the renal prognosis of FHN patients are limited to a small number of reports [1, [4] [5] [6] ; furthermore, probably due to the rarity of the disease, the risk of delayed progression to SLE has never been studied in a large cohort of paediatric patients with FHN.
Herein, we describe treatment choices and outcomes of 42 young patients with FHN who referred to five Italian Paediatric Nephrology Units during the last 20 years.
M A T E R I A L S A N D M E T H O D S

Patient selection
This retrospective study was approved by the local Institutional Review Board and included paediatric patients (age <18 years at the time of initial visit) diagnosed with FHN. FHN was diagnosed on a variety of glomerular lesions with extensive (two or more sites in the glomerulus) complement (C1q, C3) and immunoglobulin (IgG, IgM and/or IgA) glomerular staining by IF. Patients with actual or suspected systemic disease, ANCA, ANA or anti-DNA antibodies, B or C hepatitis or HIV positivity, or dubious renal findings most likely corresponding to IgA nephropathy, Henoch-Shönlein purpura nephropathy or C3 glomerulopathy, with abundant deposition of immunoglobulin and complement factors, respectively, were excluded.
As data had been collected since the 1980s, renal pathology lesions were standardized by the local pathologist according to the 1982 WHO classification (subsequently revised in 1995 and 2004) [7] [8] [9] . IF intensity for IgG, IgM, IgA, C3 and C1q was graded on a 0 to 4þ scale.
Data collection
We retrospectively reviewed all renal biopsies performed since 1980 in the participating Paediatric Nephrology Units in Italy, including in the database only patients fulfilling the inclusion criteria.
Medical records were reviewed to extract clinical information and laboratory values at onset of disease and during followup. Monthly follow-up data were available for most patients during the active phase of their diseases and every 3-6 months thereafter. Data not available for more than 6 months were censored at the date of the last patient follow-up. Minimum followup was fixed at 6 months or longer.
Definitions
Nephrotic syndrome was defined as a proteinuria >3 g/day (>2 mg/mg creatinine in children unable to collect 24-h urines) and/or serum albumin levels <2.5 g/dL [10] . Hypertension was defined as systolic and/or diastolic blood pressure above the 95th percentile for sex, age and height [11] . Estimated glomerular filtration rate (eGFR) was calculated using the Schwartz formula [12] . Acute renal failure at onset was defined as eGFR <90 mL/min/1.73 m 2 in patients without previous renal impairment. Stages of chronic kidney disease (CKD) were defined according the K/DOQI guidelines [13] .
Percentiles and scores based on the Tanner standards for height, weight and stages of puberty were used to assess anthropometric measures [14] .
Systemic signs and symptoms were categorized according to the American College of Rheumatology (ACR) revised criteria for the classification of SLE [15] .
Outcome measures
Complete remission was defined as normal renal function and proteinuria <0.5 g/day (or urinary protein/creatinine ratio <0.5 mg/mg) in at least two consecutive measurements on subsequent visits. Partial remission was defined as stable renal function and at least 50% reduction of baseline 24-h proteinuria. Renal relapse was defined by an increase of more than 50% in 24-h proteinuria and/or by a decrease in eGFR >25% from baseline after initial complete or partial remission [16] .
Treatment evaluation
Although treatment of the FHN is not standardized, patients in the present cohort were treated as per each centre's practice with a variety of immunosuppressive medications globally
reflecting the regimens commonly used for the treatment of LN [17, 18] .
To evaluate the entity of immunosuppressive treatment, we recorded the cumulative doses of methylprednisolone pulses (MPP), of intravenous or oral cyclophosphamide (CYP), the mean daily dose per kg of prednisone (PDN), of azathioprine (AZA) or cyclosporine A (CsA) and the mean daily dose per m 2 of mycophenolate mofetil (MMF) that patients actually received. We estimated treatment intensity with a scoring system developed for LN [16] .
Induction treatment was defined as the treatment received during the first 6 months of disease. Maintenance treatment was calculated during the 12 months following induction therapy only in patients that had completed at least 18 months of follow-up.
Statistical analysis
The data of baseline characteristics were presented as numbers and percentages, means 6 standard deviations (SDs) or medians and interquartile ranges (IQRs), as appropriate. Follow-up data were expressed as medians and IQRs and were compared with the Kruskal-Wallis test. Categorical variables were expressed as number and percentage. One-way ANOVA, the Kruskal-Wallis test, v 2 or the Fisher exact test for nonparametric variables, and the Wilcoxon Mann-Whitney U test were used for within/between-group comparisons, as appropriate. Box and whisker plots were used to graph skewed distributions. The Kaplan-Meier method was used to test the probability of achieving complete or partial remission, Stage III CKD and relapse of the nephropathy. Survival times were calculated since the first treatment dose (baseline) to the event of interest. Data from patients not achieving the event were considered as censored at the time of the last available visit. The Log-rank test was used for data comparison. Univariate Cox analysis tested gender, age, weight, height, body mass index, systolic and diastolic blood pressure, hypocomplementaemia C3, C4, serum proteins, proteinuria, eGFR, the presence of ACR criteria, nephrotic syndrome, hypertension, histology classes and treatment score. Multivariable Cox analysis was carried out to test the impact of baseline covariates significantly (P < 0.1 threshold) associated with the event at the univariable analysis. All P-values are two-sided and considered significant for P < 0.05. Analyses were carried out using MedCalc (v. 2004) and SPSS (v. 2003) .
Sensitivity analyses were performed on 24-h proteinuria expressed as g/m 2 /day, and on systemic symptoms expressed according to the updated Systemic Lupus International Collaborating Clinics Classification (SLICC) criteria for SLE [19] .
R E S U L T S
Baseline patient characteristics
Overall, 147 renal biopsy were evaluated in five Paediatric Nephrology Units between 1980 and 2010. Patients having other renal or systemic diseases and those with evident SLE features at onset were excluded ( Figure 1 ).
Among 50 patients selected at onset, three were missing follow-up data and five developed overt SLE (positive ANA and/ or anti-DNA antibody) over 67.9 6 59.2 months (Figure 2 ) and FIGURE 2: Probability of developing SLE during follow-up in 47 patients with FHN at disease onset. Delayed SLE was defined as the appearance of three or more criteria allowing for the diagnosis of probable or definitive SLE according to the ACR classification [15] in patients with initial diagnosis of renal-limited FHN. Only patients with more than 6 months follow-up were included. Vertical bars represent censored data. Median follow-up duration was 64.2 (IQR 14.6-102.6) months (Table 1 ). All patients were Caucasian, aged 9.64 6 4.28 years (median 10.21 years, IQR 6.28-12.83). There were 21 males and 21 females (M:F ¼ 1:1). Blood pressure was above the normal limits for age and gender in 17 (41%) subjects (8 males). Serum C3 and C4 complement levels were normal in 28 (66.7%) and 25 (59.5%) patients, respectively.
Approximately 79% of patients presented with heavy proteinuria and nephrotic syndrome at onset and 13 (30.9%) had also impaired renal function. Median eGFR of the overall study group was 113.4 (IQR 78.8-127.4) mL/min/1.73 m 2 .
Evaluation of the presence of ACR criteria and of SLICC criteria
Ten (23.8%) patients presented other signs or symptoms at onset, according to the ACR classification. Arthritis, skin rash, neurological or immunological disorders (no anti-DNA antibodies) were recorded in 17, 5, 2 and 2% of subjects, respectively. No patient, however, had more than two ACR criteria suggestive of SLE over observation, concomitantly or subsequently.
Sensitivity analysis with the inclusion of complement data (n ¼ 39 patients) according to the SLICC classification resulted in 23 patients (59%) with at least one systemic symptom in addition to nephritis.
Gender and age differences
At onset of nephropathy, females presented more frequently with systemic symptoms and lower serum C4 levels than males [any ACR criteria 38.1 versus 9.5%, and C4 levels 12 (8.0-22.5) mg/dL versus 22.5 (13.8-29.8), respectively; or any SLICC criteria (70 versus 47.4%)], although this was not statistically significant. However, only one male (5%) had 3 SLICC criteria compared with six females (30%). Accordingly, the mean number of SLICC criteria was higher in females than in males (mean 2 versus 1.5; P ¼ 0.045). Males had significantly higher proteinuria levels than females (6.85 g/day, IQR 3.0-8.65 versus 2.72 g/day, IQR 1.85-5.10, respectively; P ¼ 0.0132), even when due to the young age of patients proteinuria was corrected for body surface area (5.24 g/m No significant difference in the baseline parameters was found between different age groups, except for lower serum creatinine levels in pre-pubertal than in post-pubertal children (0. Table 1 . Baseline patient characteristics of the overall study group and according to gender and age groups 
Renal pathology features
Almost half (47.6%) of patients presented with diffuse proliferative lesions similar to Class IV LN (Supplementary data, Figure S1 ). Seven (16.7%) subjects had chronic lesions at onset of nephropathy ( Table 2 ). The distribution of the overall renal lesions was similar between males and females, while it significantly differed among age groups (P ¼ 0.0340, v 2 test for trend). Lesions similar to Class II LN were observed only in prepubertal children: mean age of patients with Class II was 6.30 years versus 10.43 years of patients with any other histological class (P ¼ 0.038 for age groups; P ¼ 0.012 for age as continuous variable). No between-groups difference was observed in the IF intensity. Table 3 shows detailed treatment regimens. At induction, females received a significantly higher cumulative dose of cyclophosphamide than males (4404 6 1094 versus 3192 6 1073 mg/m 2 , normalized for body surface, P ¼ 0.019). Pre-pubertal children received a significantly higher steroid daily dose at induction than post-pubertal ones (1.78 6 0.41 versus 1.09 6 0.44 mg/kg/day, P < 0.001). There was no age or Table 3 . Cumulative immunosuppressive treatment of the overall study group and according to gender and age groups Variables expressed as number and percentages were compared using v 2 test; variables expressed as mean 6 SD were compared using one-way ANOVA. 
Treatment
Data are expressed as n (%) or median (IQR). Class I, normal glomeruli; Class II, pure mesangiopathy with mesangial widening and/or mild to moderate hypercellularity; Class III, focal segmental glomerulonephritis with mild or moderate mesangial alterations (active, sclerosing or both); Class IV, diffuse glomerulonephritis with severe mesangial, endocapillary, or mesangio-capillary proliferation and/or extensive subendothelial deposits (active, sclerosing or both); Class V, diffuse membranous glomerulonephritis (pure or associated with lesions of categories II, III or IV); Class VI, advanced sclerosing glomerulonephritis. The overall burden of treatment of the patient group overall, as measured by the treatment intensity score (TIS), was 1.51 6 0.83 at induction (n ¼ 42) and 0.82 6 0.66 at maintenance (n ¼ 30) (Table 3) . Males had a lower TIS at induction than females (1.20 6 0.61 versus 1.82 6 0.92; P ¼ 0.013); TIS on maintenance was similar among genders ( Figure 3A) .
Pre-pubertal and post-pubertal children had similar TIS both at induction and at maintenance ( Figure 3B ).
To explore the interaction between female gender and younger age on the TIS, patients were divided into four subgroups (Supplementary data, Figure S2 ): pre-pubertal females had a significantly higher induction TIS than the remaining patients overall (1.97 6 0.93 versus 1.28 6 0.69; P ¼ 0.009) and than pre-pubertal males taken separately (1.19 6 0.33; P ¼ 0. 018). Post-pubertal females had not received a significantly more intense treatment than other patients (mean TIS 1.52 6 0.91).
Of note, the time delay from onset of nephropathy to the start of immunosuppressive treatment in females was higher than in males [median 0.53 (IQR 0-2.63) months versus median 0.0 (IQR 0-0.62) months; P ¼ 0.0430].
Outcome results
After a median follow-up of 64.2 (14.6-102.6) months, 92.9 and 76.2% of patients had achieved partial and complete remission, respectively ( Figure 4A and B) .
The median time for partial and complete remission in the overall study group was 2.78 (1.64-5.19) and 7.51 (4.34-10.19) months, respectively. There were no significant age and gender differences in the probability of both partial and complete remission, although pre-pubertal children and males showed a trend towards higher probability of complete remission (subgroup analysis for pre-pubertal males P ¼ 0.052) (Supplementary data, Figure S3 ).
After 20 years most patients had normal renal function. With the exception of two patients with renal failure at onset, no additional patient reached CKD during follow-up.
Probability of relapse and characteristics of patients with relapse
Overall, 7 (18%) patients relapsed on average 42.0 (10.5-87.0) months after achieving remission.
Relapsing children were younger and more frequently male than non-relapsing ones, although this was not statistically significant (7.52 6 4.46 versus 9.88 6 4.16 years, P ¼ 0.188, and 71.4 versus 46.9% of males, P ¼ 0.250, respectively; Supplemen tary data, Table S1 ). Consistently with younger age at onset, baseline creatinine levels were borderline significantly lower in relapsing patients than in those who did not relapse (0.49 mg/ dL, IQR 0.46-0.68 and 0.7 mg/dL, IQR 0.58-1.07, respectively; P ¼ 0.0552). However, there were no significant differences in eGFR (119.6 mL/min/1.73 m At survival analysis, the risk of relapse did not significantly differ among age and gender groups. 
| | | | | | | | | | | |
Analysis of outcome predictors
The presence of any ACR criteria and of both C3 and C4 hypocomplementaemia were significantly negatively associated with complete remission by univariable logistic regression [hazard ratio (HR) À0.344, 95% confidence interval (CI) À0.644 to À0.044, P ¼ 0.026; and HR 0.294, 95% CI 0.030-0.558, P ¼ 0.030, respectively] and by multiple regression analysis (HR À0.368, 95% CI À0.685 to À0.052, P ¼ 0.024; and HR 0.339, 95% CI 0.064-0.613, P ¼ 0.017, respectively), even when adjusted for the main baseline covariates (gender, age at onset No baseline variable predicted the risk of complete remission, partial remission or relapse both by the univariable and multivariable Cox regression analysis (Table 4 and Supplementary data, Tables S3 and S4).
D I S C U S S I O N
In this retrospective observational study, we report the outcome of Italian children and adolescents with FHN and negative lupus serology not fulfilling the ACR criteria for SLE.
In our cohort, we found that a significant proportion of patients with FHN, presenting the typical histological features of LN and consequently treated as LN, had a good renal outcome.
The long follow-up of our cohort highlighted some potential risk factors associated with the progression of FHN, in particular younger age, female gender and systemic symptoms suggestive of SLE. These, when present, may expose patients to the risk of progressive CKD up to end-stage renal disease (ESRD). This is consistent with the past observation that half of young patients with FHN, particularly those who developed systemic symptoms of SLE over follow-up and were not adequately treated, may progress to significantly impaired kidney function [1, 16] .
Treatment of FHN is not yet standardized. Most patients are generally treated with a wide variety of immunosuppressive medications according to a biopsy-based algorithm shaped on the same scheme adopted in the treatment of LN, based on the impression that the similarity between FHN and the typical renal lesions of SLE may derive from a common pathogenic mechanism.
Indeed, FHN encompasses a set of renal lesions that are often indistinguishable from LN but patients lack the characteristic ACR criteria necessary for SLE diagnosis.
However, data on outcome of this particular patient population are too scant to define the best treatment strategies, since clinical and histopathological definition of FHN, or renal-limited or seronegative lupus-like nephritis, has not been standardized so far, leading to difficulties in designing adequately powered trials.
After the first report by Jones and Magil [20] who described a patient with nonsystemic mesangiopathic glomerulonephritis with 'full-house' IF and no sign of systemic disease, a number of isolated reports have been reported on renal diseases resembling LN but lacking clinical and serological evidence of SLE [21] [22] [23] [24] [25] .
In this journal, Huerta et al. [6] described four patients with IgG-dominant immune complex-mediated glomerulonephritis characterized by a variety of pathological findings strongly suggestive of LN including: (i) 'full house' IF staining for IgG, IgM, IgA, C3 and C1q; (ii) extraglomerular immune deposits (tubules, interstitium or vessels); (iii) combined mesangial, subendothelial and subepithelial immune deposits; and (iv) endothelial TRI, although not simultaneously.
Similarly, in 2004 Sharmann et al. [4] reported on nine patients with seronegative LN with: (i) positivity for all three immunoglobulins; and (ii) electron-dense deposits in at least two locations (subepithelial, subendothelial and mesangial).
More recently, other authors referred to FHN as C1q nephropathy, in cases of FHN with dominant C1q staining at IF analysis as the diagnostic hallmark of disease. However, this label does not allow distinction between different histological patterns including minimal change disease/focal segmental glomerulosclerosis, MPGN and FHN, as previously shown in 1985 by Jennette and Hipp on 800 renal biopsy specimens evaluated for C1q deposition [3] . In such cases, the deposition of C1q may be attributable to non-specific classical complement pathway activation rather than to an ongoing immune-mediated disorder [26, 27] .
In 1999, Gianviti et al. [1] reported on 14 paediatric patients with FHN who were diagnosed on the basis of the histological criteria previously proposed by Jones and Magil [20] , namely an extensive IF characterized by a predominant positive IgG and positive IgA and/or IgM, C3 and C1q staining on a variety of light microscopy lesions resembling different stages of LN.
We adopted the IF criteria and consequently diagnosed FHN in patients having renal histological lesions compatible with LN by light microscopy, and 'full-house' pattern by IF. We also decided to maintain the term FHN in our cohort of patients. The full-house IF pattern, in particular, is the main characteristic that differentiates FHN from lesions with nonspecific deposition of C1q. We also preferred not to label these patients as seronegative or renal-limited lupus nephritis, since only a minority of them went on to develop the diagnostic criteria of SLE over a long follow-up. Notably, in the present cohort 5 of the initial 50 patients (10%) were excluded as they developed overt SLE over time and were therefore described previously as 'true' LN [16] . The high frequency of proliferative lesions and diffuse immune deposit distribution in patients with FHN, resembling LN, clearly indicates a severe immune process that warrants aggressive immunosuppressive treatment. However, this study shows that most patients will never develop sufficient criteria to be labeled as SLE. In such cases the cost of a wrong and psychologically devastating diagnosis may be higher than underestimating the diagnosis in patients who are invariably destined to receive immunosuppressive treatment based on their histological lesions.
We found that pre-pubertal males tended to have a borderline higher probability of complete remission and, although not statistically significant, of relapse. However, intensive immunosuppressive treatment may have prevented a worse prognosis in the majority of cases (only 2 of 42 patients progressed to ESRD).
The presence of any systemic symptom according to the ACR classification as well as hypocomplementaemia negatively correlated with the achievement of complete remission even when corrected for proteinuria, gender and age. Interestingly females, especially pre-pubertal ones, had more frequently systemic symptoms and hypocomplementaemia at onset; they were treated later regarding the time of diagnosis but more aggressively than males at induction. This approach may have more effectively suppressed disease activity in younger females who thus tended to have fewer relapses compared with males. Since genders were equally distributed among different histology classes, and since treatment schedules were titrated on histology lesions, we do not know exactly why females received more intense immunosuppression than males. However, female gender and systemic symptoms suggestive of SLE, although not enough to define a diagnosis, may well have induced clinicians to lean towards SLE and to adopt a more aggressive approach to the disease in such cases. Therefore, girls, particularly those with systemic symptoms who might have been less prone to achieve complete remission, had overall a good prognosis, similar to males-who conversely had more frequently an isolated renal disease-since they received more intense immunosuppressive treatment.
Some patients with FHN have been reported to develop a number of ACR criteria with time and to be subsequently diagnosed as delayed SLE [1, 16] . Moreover, the majority of paediatric SLE patients present with isolated renal or neurological involvement [28, 29] , and the limited number of ACR criteria may not allow to diagnose appropriately an onset of SLE in children. Despite the fact that hypocomplementaemia is frequent and highly specific for SLE, for many years it has not been considered adequately sensitive to constitute a criterion for diagnosis [30] . The recent updated SLICC classification of SLE [19] solved many concerns that have arisen with the initial 1982 classification, and finally included low complement as a separate immunologic criterion for diagnosis. Notably, data from our cohort showing that hypocomplementaemia, more frequent in females, may predispose to a worse prognosis, suggest the hypothesis that at least those FHN patients with low complement levels may correspond to milder forms of LN that have not developed a sufficient number of criteria under treatment. Others, without clear signs of hyper-reactivity of the immune system, may have a different disease exclusively limited to the kidney, with a different prognosis and potentially a different pathogenesis. The absence of female predominance in patients with FHN, as opposed to SLE, may be a finding in support of this hypothesis.
In an observational study on LN from our group [16] we found that patients with FHN and delayed onset of SLE during follow-up who presented with less severe renal lesions than those with an overt SLE since onset, received less intense induction treatment and consequently had a worse prognosis. This observation should lead to ensuring intense induction regimens in all forms of FHN allowing achievement of sustained remission. This attitude may lead to over-treating some patients; however, poor prognosis of undertreated progressing forms [1] favours, in our view, a more aggressive attitude. A recent case report series of four female patients with 'lupus-like nephritis' suggests that also in adults these renal lesions may have a poor prognosis [6] . On the other hand, patients in our cohort with FHN that did not develop SLE during follow-up appear to have a better course than those with SLE. This result may be due to aggressive induction treatment. However, as time from remission elapses, these patients may be good candidates for tapering and possibly discontinuation of their maintenance treatment. This suggestion is further supported by evidence in other patients with 'incomplete lupus' who did not develop other SLE criteria over a 3-year follow-up [31] and may have a good prognosis.
Thus, distinguishing at disease onset between patients who may go on to develop systemic or serological features of SLE, and are at major risk for progressive CKD [1, 16] , from those with 'primary FHN', who may have a benign course, would be clinically relevant, since the risk of chronic immunosuppression may overcome potential benefits particularly in a young population.
Recently, a pilot study from L'Erario et al. suggested that the presence of immune deposits on the skin IF may help to distinguish between 'primary FHN' and FHN leading to delayed onset SLE [32] . Moreover, LN frequently associates with the presence of tubuloreticular inclusions by electron microscopy (EM), which are considered highly suggestive of LN as they are rarely seen in other renal diseases [2, 6] . Thus, combining data from clinical evaluation of ACR criteria, skin IF and/or renal biopsy including EM when possible may help to identify progressive and non-progressive forms of FHN (Supplementary data, Figure S4) .
Finally, genetic studies may help in more dubious cases to exclude forms related to complement system deregulation, typically characterized by predominant glomerular C3 deposition and C3 hypocomplementaemia, since these insidious forms [33, 34] .
Limitations
Our study was retrospective and was not designed to evaluate efficacy and adverse effects of treatments, which differed between various centres, according to their own clinical practice on management of FHN.
Reading of renal histology was not centralized; many centres did not systematically use EM studies and we did not fix the presence of TRIs as an inclusion criterion, thus the exact proportion of patients with TRI in the study group cannot be known.
Despite the long follow-up of our cohort, we failed to identify predictors of remission or relapse; the small sample size combined with the uncommon evidence of ESRD in this population, probably related to the achievement of remission in most patients, may have reduced the power of the analyses.
Nevertheless, the present series represents the largest paediatric cohort assembled to analyse medium-and long-term outcome of FHN reported to date. Smaller patient series have been reported and there are difficulties in comparing patients due to different inclusion criteria, histology definition and rarity of disease in children.
Conclusion
FHN has an overall good prognosis but it may represent an early manifestation of SLE and consequently it warrants adequate therapeutic approaches. Younger age, female gender and systemic symptoms constitute the most alarming clinical variables that induce clinicians to use an aggressive treatment approach to the disease. Prospective studies on paediatric populations are needed to identify more reliable predictors of renal outcome, according to severity of both clinical and histological features.
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